Erudio Healtherudio.com
Drug
Mitomycin trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying mitomycin: MoonRISe-3. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 8 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| MoonRISe-3 NCT06919965 · Janssen Research & Development, LLC | high-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations | Phase 3 | 76 | 13 | Focused | Nov 14, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| SunRISe-5 NCT06211764 · Janssen Research & Development, LLC DeepView → | recurrent high-risk non-muscle-invasive bladder cancer after BCG | Phase 3 | Deep | View | |||
| S1806 NCT03775265 · National Cancer Institute (NCI) DeepView → | localized muscle invasive bladder cancer | Phase 3 | Deep | View | |||
| EV-309 NCT07566156 · Astellas Pharma Global Development, Inc. DeepView → | muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| KEYNOTE-992 NCT04241185 · Merck Sharp & Dohme LLC DeepView → | muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| PARRC NCT06770582 · National Cancer Institute (NCI) StandardView → | high-grade T1 bladder cancer | Phase 2 | Standard | View | |||
| RETAIN NCT02710734 · Fox Chase Cancer Center FocusedView → | Not given | Phase 2 | Focused | View | |||
| INSPIRE NCT04216290 · National Cancer Institute (NCI) FocusedView → | stage III node-positive bladder urothelial carcinoma | Phase 2 | Focused | View | |||
| RETAIN-3 NCT07908979 · Fox Chase Cancer Center FocusedView → | muscle-invasive bladder urothelial carcinoma | Phase 2 | Focused | View | |||